The molecular-targeted therapy in advanced differentiated thyroid cancer

郭　晔

doi:10.3969/j.issn.1007-3969.2016.01.005

您当前的位置：

首页 >

文章列表页 >

The molecular-targeted therapy in advanced differentiated thyroid cancer

更新时间：2025-12-31

- The molecular-targeted therapy in advanced differentiated thyroid cancer
- China Oncology Vol. 26, Issue 1, Pages: 31-34(2016)
- 作者机构：
  
  复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2016.01.005
  CLC：
- Published Online：26 February 2016，
  
  Published：26 February 2016
- 稿件说明：
移动端阅览
郭　晔. 晚期分化型甲状腺癌的分子靶向治疗[J]. 中国癌症杂志, 2016, 26(1): 31-34.

郭　晔. The molecular-targeted therapy in advanced differentiated thyroid cancer[J]. China Oncology, 2016, 26(1): 31-34.
郭　晔. 晚期分化型甲状腺癌的分子靶向治疗[J]. 中国癌症杂志, 2016, 26(1): 31-34. DOI： 10.3969/j.issn.1007-3969.2016.01.005.

郭　晔. The molecular-targeted therapy in advanced differentiated thyroid cancer[J]. China Oncology, 2016, 26(1): 31-34. DOI： 10.3969/j.issn.1007-3969.2016.01.005.

摘要

随着针对分化型甲状腺癌研究的深入，其特征性的分子分型和信号转导通路得以揭示，从而促进了分子靶向治疗的发展。对于放射性碘治疗失败的分化型甲状腺癌，索拉非尼和乐伐替尼等针对血管内皮生长因子通路的多靶点抑制剂被证明具有明显的抗肿瘤活性。此外，其他选择性的单靶点抑制剂以及促放射性碘摄取药物均显示出一定的治疗效果，而个体化的基因检测将为未来个体化的分子靶向治疗奠定基础。

Abstract

Along with the extensive understanding of differentiated thyroid cancer (DTC)

its distinct molecular genotype and signaling pathway was revealed

which improved the development of molecular-targeted therapy. Regarding radioactive iodine-refractory DTC

multiple multikinase inhibitors including sorafenib and lenvatinib

which target vascular endothelial growth factor (VEGF) pathway

were proved to be effective. Moreover

selective inhibitors and redifferentiation agents were shown to be promising. In the future

individual genetic testing would provide more specific information in directing individualized molecular-targeted therapy.

关键词

Keywords

references

Views

1865

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in external beam radiotherapy (EBRT) for differentiated thyroid cancer

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in ultrasound, CT, MRI and ablation of thyroid nodules and differentiated thyroid cancer

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in nuclear medicine diagnosis and treatment of differentiated thyroid cancer

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: precision treatment guided by genotyping

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: perioperative assessment and management of parathyroid function and precision individualized management of postoperative TSH suppression in adults with differentiated thyroid cancer

Related Author

Xiaorong HOU

Xiaoliang LIU

Ruyu LIU

Chenyi WANG

Bo ZHANG

Yihan ZHAO

Yansong LIN

Hao WANG

Related Institution

Department of Radiation Oncology, Peking Union Medical College Hospital & Chinese Academy of Medical Sciences

National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Center of Respiratory Medicine, China-Japan Friendship Hospital

Department of Ultrasound, China-Japan Friendship Hospital

Japan Friendship Hospital (Institute of Clinical Medical Sciences), Peking Union Medical College, Chinese Academy of Medical Sciences,, China

Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine

AI问答

⁰